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Abstract
Evidence suggests that increased hydrolysis and/or uptake of triglyceride-rich lipoprotein particles in skeletal muscle can be involved in
insulin resistance. We determined the steady state mRNA levels of the low-density lipoprotein-related receptor (LRP) and lipoprotein lipase
(LPL) in skeletal muscle of eight healthy lean control subjects, eight type 2 diabetic patients and eight nondiabetic obese individuals. The
regulation by insulin of LRP and LPL mRNA expression was also investigated in biopsies taken before and at the end of a 3 h euglycemic
hyperinsulinemic clamp (insulinemia of about 1 nM). LRP mRNAwas expressed in human skeletal muscle (1.3F 0.1 amol/Ag total RNA in
control subjects). Type 2 diabetic patients, but not nondiabetic obese subjects, were characterized by a reduced expression of LRP (0.8F 0.2
and 1.3F 0.3 amol/Ag total RNA in diabetic and obese patients, respectively; P< 0.05 in diabetic vs. control subjects). Insulin infusion
decreased LRP mRNA levels in muscle of the control subjects but not in muscle of type 2 diabetic and nondiabetic obese patients. Similar
results were found when investigating the regulation of the expression of LPL. Taken together, these results did not support the hypothesis
that a higher capacity for clearance or hydrolysis of circulating triglycerides in skeletal muscle is present during obesity- or type 2 diabetes-
associated insulin resistance.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Evidence has been accumulated suggesting that increased
lipid availability in skeletal muscle is a cause of insulin
resistance in obesity and in type 2 diabetes [1,2]. Based on
the initial finding by Randle et al. [3], it has been postulated
that the elevation of circulating free fatty acid concentra-
tions, as frequently observed in obese and in diabetic
patients, was one of the culprits in the reduced action of
insulin [4–6]. A number of observations also suggest that
triglyceride availability and hydrolysis in skeletal muscle
could be involved in insulin resistance [2]. For instance,
infusion of lipid emulsions, composed of triglycerides,
reduced insulin action both in humans and animal models
[5–8]. However, most of the infused lipids combine with
circulating apoproteins to form lipoproteins that are sub-
sequently cleared from the circulation [9]. It has also been
demonstrated that high fat feeding induces insulin resistance
[10,11]. Dietary fat generally forms chylomicrons that are
hydrolyzed by lipoprotein lipase (LPL) in adipose tissue and
skeletal muscle capillaries [12]. Thirty-five years ago, it was
reported that chylomicrons could inhibit glucose uptake in
rat heart [13]. Furthermore, overexpression of LPL in mice
skeletal muscle leads to intramuscular lipid accumulation
and insulin resistance, without any increase in plasma free
fatty acid [14,15]. In humans, recent data also clearly
demonstrated that accumulation of intramyocellular trigly-
cerides is strongly associated with insulin resistance [16,17].
All these results therefore suggest that transfer of lipids from
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triglyceride-rich lipoprotein particles to skeletal muscle can
be involved in lipid-induced insulin resistance.
The low-density lipoprotein (LDL) receptor-related pro-
tein (LRP) is a large multiligand receptor that belongs to the
LDL receptor gene family [18] and that has been shown to
play a role, in cooperation with the LDL receptor, in the
removal of chylomicron remnants from the circulation [19].
In rat adipose tissue, insulin up-regulates LRP gene expres-
sion, and this effect is thought to be involved in the stim-
ulation by insulin of the endocytic uptake of remnant
lipoproteins by adipocytes [20]. In addition, fed rats
expressed more LRP and accumulated significantly more
chylomicrons in adipose tissue than did fasted animals [20].
In adipose tissue, insulin and feeding also increase the
expression and activity of LPL, the enzyme that catalyses
the hydrolysis of triglycerides and thus controls the rate of
entrance of fatty acids into fat cells [12]. Therefore, in a post-
prandial situation, a coordinate stimulating action on LRP
and LPL could lead to an increased uptake of triglycerides
and fatty acids from remnant lipoproteins in adipocytes.
Little data is available regarding the regulation of lipid
uptake in skeletal muscle and its relationship with insulin
resistance in humans. The expression and the regulation of
LRP in human skeletal muscle is not known, and only a few
studies have investigated the expression of muscle LPL in
pathological conditions of insulin resistance [21–23]. As
discussed above, increased availability and uptake of lipids
from triglyceride-rich lipoproteins could be involved in fat
accumulation within the muscle cells. However, it is not clear
whether the disturbances in lipid metabolism in skeletal
muscle result from elevated circulating levels of lipids or
from higher hydrolysis and clearance of plasma lipoproteins
and triglycerides in skeletal muscle. According to this latter
hypothesis, it might be expected that the expression and
activity of LPL and other proteins involved in lipid transfer,
such as LRP, are increased in skeletal muscle of insulin-
resistant patients. The aim of this study was therefore to
determine LRP and LPL mRNA expression in skeletal
muscle of insulin-resistant patients. In addition, we have
investigated the in vivo regulation by insulin of the expres-
sion of these two genes in muscle from healthy lean controls,
nondiabetic obese subjects and type 2 diabetic patients.
2. Materials and methods
2.1. Subjects
Twenty-four subjects (eight lean, eight obese nondiabetic
and eight type 2 diabetic subjects) who participated in a
study aiming to investigate the regulation of gene expres-
sion by insulin in human tissues [24,25], were selected for
the present work. Their characteristics are presented in Table
1. None of the healthy lean subjects had a familial or
personal history of diabetes, obesity or hypertension. None
of the obese subjects had impaired glucose tolerance as
assessed by classical oral glucose tolerance test (2 h plasma
glucose concentration below 7.8 mM following a 75 g oral
glucose test, according to the revised American Diabetes
Association criteria). All participants gave their written
consent after being informed of the nature, purpose and
possible risks of the study. The experimental protocols were
approved by the Ethical Committees of the Hospices Civils
de Lyon (Lyon, France).
2.2. Euglycemic hyperinsulinemic clamp
To investigate insulin action on gene expression, all
subjects were studied using the euglycemic hyperinsuline-
mic clamp technique after an overnight fast. The clamp was
performed as previously described [24,26], with a rate of
insulin infusion of 450 pmol/m2 body surface area/min for 3
h. Serum insulin concentration was measured by commer-
cial radioimmunoassay, and serum metabolite concentra-
tions were determined by enzymatic assays [26].
2.3. Skeletal muscle biopsies
Muscle samples (vastus lateralis) were taken under local
anesthesia (2% Lidocain without adrenaline), 3 h before and
at the end of the hyperinsulinemic clamp period by percuta-
neous biopsies using a Weil Blakesley plier, as previously
described [24,25]. The average weight of the muscle sam-
ples were 51F 4 mg wet weight (n = 48) with no difference
between samples from lean, obese and type 2 diabetic
subjects or before and after clamp. Possible contamination
of the muscle biopsies by fat cells was unlikely since the
Table 1
Characteristics of the subjects
Lean Obese Type 2
diabetic
n 8 8 8
M/W 2/6 1/7 4/4
Age (years) 46F 4 43F 5 52F 2
BMI (kg/m2) 23F 1 35F 2a 30F 1a
Glucose (mM) 4.9F 0.9 5.0F 0.1 11.8F 1.1a,b
Insulin (pM) 41F 5 83F 21c 55F 10
Cholesterol (mM) 5.5F 0.3 5.6F 0.3 5.0F 0.4
NEFA (AM) 436F 42 629F 61c 652F 53a
Triglycerides (mM) 0.8F 0.1 1.2F 0.1c 1.3F 0.1c
Clamp studyd
Glucose (mM) 4.4F 0.2 4.4F 0.1 5.0F 0.1e
Insulin (pM) 1015F 67 1157F 157 1153F 160
Glucose disposal rate
(mg/kg/min)
9.5F 1.5 4.3F 0.8a 4.1F 0.5a
Plasma metabolite and hormone concentrations were determined after an
overnight fast.
a P < 0.01 vs. lean subjects.
b P < 0.01 vs. obese subjects.
c P < 0.05 vs. lean subjects.
d Measured during the last hour of the clamp.
e P < 0.05 vs. obese subjects.
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expression level of leptin mRNAwas found to be below the
detection limit of a very sensitive RT-competitive PCR (RT-
cPCR) assay [27] in these muscle samples (data not shown).
2.4. Total RNA preparation
Tissue samples were crushed in liquid nitrogen, and total
RNA was prepared according to a modified procedure of
Chomczynski and Sacchi [28]. Average yields of total RNA
were 25F 3 Ag/100 mg, and were not significantly different
in tissues from lean, obese and type 2 diabetic subjects,
before or after the clamp. Integrity of the RNA preparations
was checked by electrophoresis in agarose gel stained with
ethidium bromide. Total RNA solutions were stored at  80
jC until quantification of LRP mRNA.
2.5. Quantification of LRP mRNA
Human LRP mRNA was quantified by RT-cPCR, which
consists of the co-amplification of target cDNAwith known
amounts of a specific DNA competitor molecule added in
the same PCR tube [29]. To generate a specific LRP
competitor DNA, a 440-bp-long cDNA fragment was
obtained by RT-PCR using 5V-TGGAACAGATGGCCATC-
GAC-3Vas sense primer (nucleotides + 1311 to + 1330 of
the human LRP cDNA sequence, and 5V-CGAGTTGG-
TGGCATAGAGAT-3V(nucleotides + 1731 to + 1750) as
antisense primer. The competitor was obtained by deleting
30 bp (from nucleotide + 1330 to + 1360) using a PCR-
based mutagenesis strategy as described by Schneeberger
and Zeillinger [30]. The LRP competitor fragment (406 bp)
was subcloned (pGEM-T, Promega) and the plasmid was
purified, carefully quantified and stored at  20 jC. Work-
ing solutions (20 amol/Al to 10 3 amol/Al) were prepared
by serial dilutions in 10 mM Tris–HCl (pH 8.3), 1 mM
EDTA buffer.
For the assay of LRP mRNA, the reverse transcription
reaction was performed from 0.2 Ag of tissue total RNAwith
2.5 U of thermostable reverse transcriptase (Tth, Promega,
Charbonie`res, France), in the presence of 15 pmol of LRP-
specific antisense primer. The conditions of the reaction have
been described in detail previously and warranted optimal
synthesis of first-strand cDNA [29]. For the competitive PCR
amplification, the reverse transcription medium was added to
a PCR master mix (10 mM Tris–HCl pH 8.3, 100 mM KCl,
0.75 mM EGTA, 5% glycerol) containing 0.2 mM deoxy-
nucleoside triphosphates, 5 U of Taq polymerase (Life
Technologies, Cergy Pontoise, France), 30 pmol of LRP
antisense primer and 45 pmol of LRP sense primer. The
sense primer was 5V-labeled with the CY-5 fluorescent dye
(Eurogentec, Seraing, Belgium). The final volumewas 100 Al
and four aliquots of 20 Al were transferred to 0.5-ml micro-
tubes containing 5 Al of a defined working solution of the
LRP competitor. After 120 s at 94 jC, the PCRmixtures were
subjected to 40 cycles of PCR amplification with a cycle
profile including denaturation for 60 s at 94 jC, hybridization
for 60 s at 58 jC and elongation for 60 s at 72 jC. The PCR
products were separated and analyzed by polyacrylamide gel
electrophoresis (6%) using a ALFexpress DNA sequencer
(Pharmacia, Upsala, Sweden) and the Fragment Manager
software (Pharmacia). The RT-cPCR assay of LRP mRNA
was validated using known amounts of an in vitro synthe-
sized LRP RNA fragment (Riboprobe System, Promega), as
recommended [29]. LPL mRNA levels were determined
using a RT-cPCR assay previously described [26].
2.6. Statistical analysis
All data are presented as meanF S.E. between group
comparisons were done using Kruskal–Wallis one-way
ANOVA followed by Mann–Whitney U-test when the
ANOVA indicated a significant difference. Wilcoxon’s test
for paired values was used when comparing mRNA levels
before and after clamp. Correlation coefficients were calcu-
lated using Spearman’s test. P < 0.05 was considered statisti-
cally significant.
3. Results
Under basal conditions, after an overnight fast, LRP
mRNA is expressed in human skeletal muscle as shown in
Fig. 1. When comparing the mRNA levels of LRP in the
muscle of healthy lean control, type 2 diabetic and non-
diabetic obese subjects, the Kruskal–Wallis test indicated a
tendency for a difference (P= 0.097). The non-parametric
Mann–Whitney U-test showed that type 2 diabetes, but not
obesity, was associated with a significant (P= 0.035) reduc-
Fig. 1. Basal mRNA levels of LRP in skeletal muscle from lean, obese
nondiabetic and type 2 diabetic subjects. The steady state concentrations of
LRP mRNAwere determined by RT-cPCR in skeletal muscle biopsies taken
after an overnight fast in healthy lean subjects, obese nondiabetic and type 2
diabetic patients as indicated under Materials and methods. Data are
meanF S.E. *P < 0.05.
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tion in the abundance of LRP mRNA (Fig. 1). When the data
of the control subjects and the type 2 diabetic patients were
analyzed together, there was a trend for a negative correlation
between fasting insulinemia and basal LRP mRNA levels
(r = 0.50, P= 0.058). This correlation was not found when
the obese subjects were included in the analysis. Skeletal
muscle LRP mRNA concentration was not associated with
either fasting glycemia, plasma non-esterified fatty acid
concentrations, plasma triglyceride concentrations, plasma
cholesterol concentrations or insulin-stimulated whole body
glucose uptake (data not shown). In the same tissue samples,
LPL mRNA expression was significantly lower in type 2
diabetic patients than in control subjects (14F 3 vs. 54F 6
amol/mg of total RNA, P= 0.006). In addition, reduced LPL
expression was also observed in themuscle of the nondiabetic
obese subjects (23F 5 vs. 54F 6 amol/mg of total RNA,
P= 0.04). There was no correlation between LRP and LPL
mRNA levels in skeletal muscle. It should be noted that in
contrast to LRP and LPL, the mRNA levels of a number of
other genes, such as h-actin, insulin receptor and Glut 4, were
not different between groups in muscle preparations from the
same type 2 diabetic and obese subjects (data not shown), as
previously reported [25].
Hyperinsulinemia for 3 h produced a significant
(P= 0.012) decrease in LRP mRNA levels in the skeletal
muscle of lean control subjects (Fig. 2). In contrast, LRP
mRNA expression was not modified during the hyperinsu-
linemic clamp in the muscle of obese nondiabetic subjects
or of type 2 diabetic patients. Similar changes were
observed in response to insulin for LPL expression (Fig.
3). LPL mRNA levels were significantly reduced during the
hyperinsulinemic clamp in control subjects ( 21F 8%,
P= 0.018), but not in type 2 diabetic and in obese patients.
4. Discussion
In this study, it was demonstrated that LRP was
expressed in human skeletal muscle and that insulin infusion
for 3 h reduced LRP mRNA levels in healthy lean subjects.
Furthermore, there was an about 2-fold reduction in the
abundance of LRP transcripts, and a lack of response to
insulin infusion, in the muscle of type 2 diabetic patients.
Similar results were observed for LPL mRNA expression.
LRP has been shown to be involved, among other
functions [31], in the removal of chylomicron remnants
from the circulation [19]. It is mainly expressed in liver and
adipose tissue where most of the clearance of chylomicrons
occurs [31]. The presence of LRP mRNA, although at rather
low levels (about 10-fold less LRP than LPL transcripts) in
human muscle and the fact that its expression was regulated
by insulin, suggest that LRP protein might be expressed at
the membrane of the myocytes and have a biological
function. With respect to liver and adipose tissue, skeletal
muscles are not considered as major sites of chylomicron
removal but evidence suggests that higher targeting of
lipoproteins and increased lipid uptake may play a role in
the development of insulin resistance [2]. It is indeed well
Fig. 2. Regulation of LRP mRNA expression by insulin. Acute 180 min
insulin infusion significantly decreased the expression of LRP mRNA in
skeletal muscle of lean subjects ( P= 0.012) but not of obese nondiabetic
( P= 0.575) or type 2 diabetic subjects ( P= 0.735).
Fig. 3. Regulation by insulin of LPL mRNA levels. The concentrations of
LPL mRNA were determined by RT-cPCR in skeletal muscle biopsies
taken before (open boxes) and at the end (closed boxes) 3 h of
hyperinsulinemic clamp in control subjects, obese nondiabetic and type 2
diabetic patients. Insulin infusion significantly decreased the expression of
LPL mRNA in skeletal muscle of lean subjects ( P= 0.018) but not of obese
nondiabetic ( P= 0.345) or type 2 diabetic subjects ( P= 0.499). Data are
meansF S.E. *P < 0.05 vs. control subjects.
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demonstrated that infusion of lipid emulsions, composed of
triglycerides that form lipoproteins in the circulation [9],
reduced insulin action both in humans and animal models
[5–8]. Furthermore, high fat feeding induces muscle insulin
resistance [10,11], and dietary fat generally forms chylomi-
crons that are hydrolyzed by LPL in adipose tissue and
skeletal muscle capillaries [12]. Therefore, an increased
capacity for the transfer of lipids from triglyceride-rich
lipoprotein particles to the muscle cells can be involved in
lipid-induced insulin resistance. We found here that there is
no evidence for higher expression of either LRP or LPL, the
rate-limiting enzyme for the uptake of fatty acids from
circulating triglycerides, in muscle of insulin-resistant sub-
jects. Even more, there was a marked reduction in the
mRNA levels of both LRP and LPL in skeletal muscle of
type 2 diabetic patients. If the changes in mRNA abundan-
ces are translated into a reduction in LRP and LPL proteins
and activities, one must thus assume that skeletal muscle of
insulin-resistant subjects do not have increased capacity for
removal of triglycerides from the circulation. Regarding
LPL, the observed reduction in mRNA levels is in keeping
with a decreased LPL activity found in muscle of insulin-
resistant subjects [21]. For LRP and the other proteins
involved in the removal of circulating lipoproteins and the
uptake of lipids, further studies are required to verify
whether their activity is altered in insulin resistance. Never-
theless, we have recently reported that the mRNA expres-
sion of the fatty acid transport protein-1 (FATP-1) is reduced
in skeletal muscle of insulin-resistant women [32]. In
addition, it has been shown that the uptake of long chain
fatty acids in skeletal muscle is reduced in fasting conditions
in type 2 diabetic patients [33], and that the uptake of fatty
acid across the leg is decreased in women with visceral
obesity and insulin resistance [34]. Taken together, these
data strongly suggest that insulin resistance is not charac-
terized by higher capacities for the capture and uptake of
lipids in skeletal muscle. Therefore, increased availability of
triglycerides and fatty acids due to higher circulating con-
centrations, or altered intracellular lipid metabolism, seem
more likely to explain the relationship between lipids and
insulin resistance [1,2]. This might in turn down-regulate
the expression of the genes coding for the proteins involved
in lipid uptake (like LPL and LRP) through mechanisms that
are not yet determined.
Previous studies have clearly demonstrated that LRP gene
expression was up-regulated by insulin in vivo in rodent
adipose tissue [20]. In adipocytes, LRP mRNA increased
within minutes after the cells were exposed to physiological
concentrations of insulin [20]. In other cells, such as macro-
phages [35], insulin also increased LRP mRNA levels and
LRP activity, in a dose- and time-dependent manner. More-
over, insulin action on LRP expression involved both the PI
3-kinase and Ras/MAPkinase signaling pathways in macro-
phages [35]. These data demonstrated that LRP gene is a
bona fide target gene of insulin. In our study, LRP gene
expression also appeared to be regulated during insulin
infusion. However, 3 h of hyperinsulinemia reduced LRP
mRNA levels in skeletal muscle of the lean control subjects.
Similar down-regulation by insulin was observed for LPL
mRNA, in agreement with a previous study [26]. Therefore,
there is an opposing action of insulin in muscle and in
adipocytes on LPL and LRP gene expression. This result is
in keeping with the expected biological effects of insulin
which promotes an orientation of the flux of lipids to adipose
tissue where they are stored and a reduction in lipid utiliza-
tion in muscles, favoring glucose uptake. Our results showed
that the regulation by insulin of the balance between lipid
and glucose metabolisms in skeletal muscle also occurs at the
transcriptional level. For instance, it has been reported that
insulin up-regulates the expression of several genes coding
proteins of glucose metabolism, such as Glut 4 [25,26,36,37]
or hexokinase II [25,38] and we showed here that insulin
down-regulates the expression of genes involved in the
uptake of lipids, such as LPL and LRP.
The effect of insulin on LPL and LRP expression is
altered in muscle from nondiabetic obese subjects and type
2 diabetic patients. Defective regulation by insulin of gene
expression has been previously documented in diabetic
patients [25,36–38]. We have demonstrated that the altered
regulation of hexokinase II, p85aPI 3-kinase and the tran-
scription factor SREBP1c was encountered in type 2 dia-
betic patients and not in nondiabetic obese subjects,
suggesting that type 2 diabetes is characterized by specific
transcriptional alterations which are not directly linked to
insulin resistance [25]. In the same group of subjects,
however, the regulation by insulin of other gene, such as
Glut 4 [25], was found to be impaired both in type 2 diabetic
patients and in nondiabetic obese subjects, suggesting that
this defect was likely a consequence of insulin resistance. In
this study, the effect of insulin on LRP and LPL mRNA
expression was also altered in type 2 diabetic patients and in
nondiabetic obese subjects, indicating that the defect, as for
Glut 4, probably results from the reduced insulin action in
the muscle of these subjects.
In conclusion, this study showed that LRP was expressed
in human skeletal muscle and that insulin, in vivo, decreased
its mRNA levels in muscle of insulin-sensitive control
subjects. In type 2 diabetic patients, the expression levels
of muscle LRP mRNA was significantly reduced compared
to healthy subjects and the regulation by insulin was altered.
Similar results were found for LPL transcripts. Taken
together, these results did not support the hypothesis that a
higher hydrolysis and/or uptake of triglyceride-rich lipopro-
tein particles in skeletal muscle can be involved in obesity-
and type 2 diabetes-associated insulin resistance.
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